The Venture Innovation Program is a 6-12 month program for Ph.D., MBA, and MD students across Canada who want to gain exposure to life sciences venture capital and start-ups, and are committed to pushing the future of life sciences innovation …
Trending at Lumira Ventures
Celebrating The Inspirational Women of Lumira Ventures: International Women’s Day 2022
Every year on March 8th, we observe International Women’s Day by honoring the social, political, economic, and cultural achievements of women globally. Additionally, the day marks a call to action for accelerating gender parity. This year’s theme is – #BreakTheBias, …
OncoMyx Appoints Robert Williamson Chief Business and Chief Financial Officer
OncoMyx Therapeutics, a privately-held oncolytic virus immunotherapy company, today announced the appointment of Robert Williamson as Chief Business and Chief Financial Officer. Mr. Williamson has more than two decades of experience in building, financing, and leading private and public biotechnology …
Rare Disease Day 2022
Today is Rare Disease Day and we at Lumira Ventures are proud of our ongoing commitment to supporting the discovery, development and commercialization of innovative therapeutic products with the potential to materially impact the lives of patients suffering from rare …
Peter van der Velden Talks All Things VC on the McRock Live Podcast
This Friday February 25th, Join Lumira Ventures Managing General Partner, Peter van der Velden for a live podcasting event hosted by McRock Capital. On this episode of McRock LIVE, Peter will be having a discussion with Chris Arsenault, Inovia Capital, …
enGene Announces Positive Preliminary Phase 1/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
enGene Inc., a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced positive results from its LEGEND study, a first-in-human Phase 1/2 clinical trial of EG-70 for the treatment …
Congruence Therapeutics Inc. Announces US$50 million Series A Financing to Advance Platform Targeting Diseases of Protein Misfolding
Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today the closing of a US$50 million, tranched, series A financing. The financing was led …
Peter van der Velden is the Keynote Speaker and Panelist at the 9th Annual Falcons’ Fortunes Pitch Competition
On Friday, February 4th, Lumira Ventures General Partner and Managing Director, Peter van der Velden will be presenting as a keynote speaker and panelist judge for FACIT’s 9th annual Falcons’ Fortunes Pitch Competition. A day showcasing six entrepreneurs working in …
XyloCor Therapeutics Expands Leadership Team with Accomplished Pharmaceutical Executives to Accelerate Clinical Development Programs and Drive Corporate Growth
XyloCor Therapeutics, a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced that it has appointed Elizabeth Tarka, M.D. as Chief Medical Officer and A. Brian Davis as Chief Financial Officer. These experienced pharmaceutical industry executives will …
Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that the company has received approval from Health Canada to test its monoclonal antibody candidate, designated EB05, as a rescue therapy for critically ill …
LQT Therapeutics Announces Collaboration with Leading Cancer Researcher
LQT Therapeutics, Inc. (“LQTT”) is pleased to announce a collaboration with the laboratory of Dr. Donald McDonnell of Duke University School of Medicine to evaluate LQTT SGK1 inhibitors as potential treatment for patients with resistant prostate and breast cancer. Despite …
Fusion Pharmaceuticals Announces Nomination Of First Targeted Alpha Therapy Candidate In Collaboration With AstraZeneca To Advance Into IND-Enabling Studies For Phase 1 Development
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced nomination of the first targeted alpha therapy (TAT) candidate under the Company’s collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN). Both companies will …
Antiva Biosciences Named Winner of Global Women’s HealthTech Award By World Bank Group and Consumer Technology Association
Honor Recognizes Companies Advancing Innovative Solutions to Improve Women’s Health and Safety in Emerging Markets Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced that …
LQT Therapeutics Announces Award by the European Joint Program for Rare Diseases for SGK1 inhibition as a novel therapeutic approach in Long QT Syndrome
Closing the gap between industry and academia to place patients directly at the center of research efforts. LQT Therapeutics, a privately-held biopharmaceutical company advancing novel SGK1 kinase therapeutics, today announced that the project, “SILENCE-LQTS: SGK1 inhibition as a novel therapeutic …
Lumira Ventures Announces Promotion of Lu Han, Ph.D. to Partner and Team Expansion
TORONTO, January 6, 2022 – Lumira Ventures, a leading North American healthcare venture capital firm, today announced the promotion of Dr. Lu Han, Ph.D., to Partner and the appointments of Dr. Suman Rao, Ph.D. as an Associate and Dr. Ai …